• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SQZ Biotechnologies Company filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Material Impairments, Leadership Update

    10/2/23 5:17:20 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SQZ alert in real time by email
    8-K
    0001604477false00016044772023-09-292023-09-29

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 29, 2023

     

     

    SQZ BIOTECHNOLOGIES COMPANY

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39662

    46-2431115

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    200 Arsenal Yards Blvd

    Suite 210

     

    Watertown, Massachusetts

     

    02472

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 617 758-8672

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    SQZB

     

    OTC Markets

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 2.05 Costs Associated with Exit or Disposal Activities.

    On September 29, 2023, the Board of Directors (the “Board”) of SQZ Biotechnologies Company (the “Company”) approved a reduction in the Company’s workforce by approximately eighty percent (the “Workforce Reduction”). The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses while it pursues strategic alternatives. The Company expects to continue to treat currently enrolled patients in its enhanced antigen presenting cell (eAPC) and activating antigen carriers (AAC) programs in HPV16+ tumors.


    The Company currently estimates that it will incur approximately $1.5 million in charges in connection with the Workforce Reduction, primarily consisting of employee-related benefits and related costs including continuation of group health insurance coverage for a specified period to the affected employees, approximately $100,000 of which is anticipated to result in cash expenditures. The Company expects that the majority of these charges will be incurred in the third quarter of 2023. The charges the Company expects to incur are subject to assumptions, and actual charges may differ from the amount disclosed in this Current Report on Form 8-K.

    Item 2.06 Material Impairments.

    The information contained in Item 2.05 above is incorporated herein by reference. Due to the Workforce Reduction and resulting reduced space requirements, the Company currently estimates that it will recognize a non-cash impairment charge of approximately $22 million related to its facility lease right of use asset and certain equipment. The Company does not expect material cash expenditures in connection with the impairment charge. The charges the Company expects to incur are subject to assumptions, and actual charges may differ from the amount disclosed in this Current Report on Form 8-K.

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    In connection with the Workforce Reduction, on October 3, 2023, the Company and each of Howard Bernstein, Ph.D., Interim Chief Executive Officer of the Company, Richard Capasso, Chief Accounting Officer of the Company, Marshelle Smith Warren, M.D., Chief Medical Officer of the Company, and Lawrence Knopf, General Counsel of the Company (collectively, the “Executive Officers”) entered into a transition agreement amending the terms of the Executive Officer’s employment agreement with the Company. The transition agreements provide for an agreed employment termination date for the Executive Officers of November 15, 2023, subject to certain early termination events, and a reduction in the current annual base salaries and expected working time commitments of the Executive Officers effective October 3, 2023, as follows: 50% for Dr. Bernstein, 25% for Mr. Capasso, 75% for Dr. Warren and 50% for Mr. Knopf.

    Following their respective employment termination dates, the Executive Officers are expected to enter into consulting agreements with the Company under which they will perform consulting services on an as-needed basis for an hourly consulting fee of $350 for Dr. Bernstein, $250 for Mr. Capasso; $275 for Dr. Warren and $300 for Mr. Knopf.

    Under each Executive Officer’s transition agreement, if the Executive Officer remains employed through the first of the Executive Officer’s agreed employment termination date, the date of a change in control (within the meaning of the Executive Officer’s employment agreement) of the Company, immediately prior to the commencement of a voluntary or involuntary insolvency proceeding of the Company under the U.S. Bankruptcy Code (or similar law) or the Company’s earlier termination of the Executive Officer’s employment other than for cause (within the meaning of the Executive Officer’s employment agreement), then, , the Executive Officer will be released from an obligation, in certain circumstances, to repay the retention recognition bonus awarded on July 10, 2023 and, if a change in control occurs prior to the Executive Officer’s employment termination date or within the 3-month period thereafter and subject to the Executive Officer signing on or before the 45th day following the Separation Date, and not revoking, a general release of claims and the Executive Officer’s continued compliance with the Executive’s Officer’s restrictive covenant obligations to the Company, the Executive Officer will be entitled to a payment equal to 25% of the Executive Officer’s average annual base salary in effect immediately prior to October 3, 2023 plus 25% of the Executive Officer’s target annual bonus amount in effect immediately prior to October 3, 2023. The foregoing termination rights supersede in their entirety the severance payments and benefits provisions of the Company’s employment agreements with the Executive Officers.

    Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to the anticipated charges associated with the Workforce Reduction, anticipated non-cash impairment charges in connection with reduced space requirements, the Company’s plans regarding the employment and subsequent consultancy of the Company’s Executive Officers, the Company’s plans to pursue strategic

     


     

    alternatives, the Company’s plans to continue to treat patients and the expected financial and operational impacts of the Company’s cost-reduction initiatives. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors, including but not limited to the important factors discussed under the caption "Risk Factors" in the Company’s Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of the date of this Current Report on Form 8-K and the Company undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SQZ BIOTECHNOLOGIES COMPANY

     

     

     

     

    Date:

    October 2, 2023

    By:

    /s/ Lawrence Knopf

     

     

     

    Lawrence Knopf

    General Counsel

     

     


    Get the next $SQZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SQZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SQZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vink Patrick V.J.J.

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:48:26 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Srivastava Sapna

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:47:28 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Schulman Amy W

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:46:40 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

      Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number

      6/15/23 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

      Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e

      5/10/23 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

      A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co

      3/22/23 4:50:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Financials

    Live finance-specific insights

    See more
    • SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

      Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic  Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated  Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented

      12/9/21 6:10:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

      Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus

      12/2/21 6:15:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    SEC Filings

    See more
    • SEC Form DEFM14A filed by SQZ Biotechnologies Company

      DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/23/24 4:31:01 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PREM14A filed by SQZ Biotechnologies Company

      PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/12/24 8:57:36 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by SQZ Biotechnologies Company

      15-12G - SQZ Biotechnologies Co (0001604477) (Filer)

      1/4/24 4:15:33 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/13/24 5:13:06 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/9/24 5:10:57 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/14/23 2:25:08 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Leadership Updates

    Live Leadership Updates

    See more
    • SQZ Biotechnologies Announces Leadership Transition

      Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company's Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a

      9/6/22 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

      Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company's Chief Financial Officer, effective immediately. Mr. Zajic has served as the company's Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role. As CFO, Mr. Zajic will continue to report to the CEO and will lead the company's finance and accounting, business development,

      7/11/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

      Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Dr. Warren will report to the CEO and lead the company's clinical development, clinical operations, translational medicine, and regulatory affairs functions. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advan

      5/31/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care